Delivery Order SPE2DB24D1205-SPE2DB25FCXTV
- Not listed
- The Defense Logistics Agency awarded a $1,944.90 delivery order to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL vials (10 mL) on July 18, 2025, with completion scheduled for July 21, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical federal vendor specializing in medical supply chain support for military and veteran healthcare...
- The Defense Logistics Agency awarded a $3,362.46 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of NovoLog 100 Unit/mL vials (10mL), with an ultimate completion date of September 19, 2025. This contract was competitively awarded without set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,250.89 to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL vials (10 mL) on June 24, 2025, with completion scheduled for June 25, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child order under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $1,296.60 for NovoLog 100 Unit/mL vials (10 mL) on August 12, 2025, with completion targeted for August 13, 2025. The contract employs firm fixed pricing with no set-aside designation, indicating competitive procurement. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this delivery order at its corporate office location in the...
- The Defense Logistics Agency awarded a $1,803.20 firm fixed price delivery order to AmerisourceBergen Drug Corp on September 2, 2025, for NovoLog 100 Unit/mL vials (10 mL units). This non-set-aside competitive award represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The pharmaceutical distributor, headquartered in Conshohocken, Pennsylvania, serves as a critical...
- The Defense Logistics Agency awarded a delivery order valued at $4,754.40 to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL vials (10 mL) on September 3, 2025, with an ultimate completion date of September 4, 2025. The contract is structured as a firm fixed price delivery order with no set-aside designation, indicating competitive award status. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of NovoLog 100 Unit/mL vials (10 mL) with a ceiling value of $1,040.41. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 29, 2025. This delivery order represents...
- This delivery order, awarded on April 24, 2025, by the Defense Logistics Agency to AmerisourceBergen Drug Corp, covers the supply of NovoLog 100 Unit/mL vials (10mL) at a ceiling value of $1,296.60. The contract utilizes firm fixed pricing with no set-aside designation, indicating it was competitively awarded. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is issued under the company's larger...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $1,696.30 for NovoLog 100 Unit/ML vials (10 mL) on August 8, 2025, with an ultimate completion date of August 11, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. The contract represents a routine pharmaceutical procurement supporting federal medical...
- The Defense Logistics Agency awarded a $6,102.42 delivery order to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL vials (10mL) on July 30, 2025, with a completion date of July 31, 2025. This is a firm fixed price, non-set-aside contract to be performed at the company's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which...
- SPE2DB24D1205Indefinite Delivery Contract
- SPE2DB24D1205-SPE2DB25FCXTVDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $11,761.94 to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL vials (10mL) on June 16, 2025, with an ultimate completion date of June 17, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999 and extends through December 2026, serving as a comprehensive global pharmaceutical support vehicle for military healthcare programs worldwide. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, maintains a significant federal contract portfolio focused on supplying medications and medical supplies to Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company's role as a pharmaceutical prime vendor under the DLA framework enables flexible fulfillment of federal medical procurement requirements across multiple therapeutic domains. This specific delivery order for NovoLog insulin reflects the company's continued support of military medical supply chains and demonstrates its capability to meet federal pharmaceutical distribution needs through open competition.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $11.8k | 6/16/25 |